ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3054% below fair value
$71.44+0.38 (+0.53%)
Close on Nov 13, 2026Market cap $1.64BP/E 13.5Yield –
ANI Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ANI Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $249.21M, up 52.6% year over year. For fiscal 2025 it was $202.51M, up 196.4% from the year before. Over ten years it grew 17.7% a year on average. The highest annual figure on record is $202.51M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.51M | +196.4% |
| FY2024 | Dec 31, 2024 | $68.32M | -36.0% |
| FY2023 | Dec 31, 2023 | $106.76M | +392.2% |
| FY2022 | Dec 31, 2022 | $21.69M | +190.8% |
| FY2021 | Dec 31, 2021 | $7.46M | -73.9% |
| FY2020 | Dec 31, 2020 | $28.62M | -53.1% |
| FY2019 | Dec 31, 2019 | $60.96M | -11.8% |
| FY2018 | Dec 31, 2018 | $69.10M | +22.8% |
| FY2017 | Dec 31, 2017 | $56.26M | +32.6% |
| FY2016 | Dec 31, 2016 | $42.42M | +7.1% |
| FY2015 | Dec 31, 2015 | $39.60M | +65.8% |
| FY2014 | Dec 31, 2014 | $23.88M | +1089.4% |
| FY2013 | Dec 31, 2013 | $2.01M | +282.5% |
| FY2012 | Dec 31, 2012 | $525.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $71.93M | +22.2% |
| Q2 FY2026 | Jun 30, 2026 | $60.10M | +61.7% |
| Q1 FY2026 | Mar 31, 2026 | $59.81M | +21.8% |
| Q4 FY2025 | Dec 31, 2025 | $57.38M | +214.9% |
| Q3 FY2025 | Sep 30, 2025 | $58.87M | – |
| Q2 FY2025 | Jun 30, 2025 | $37.17M | +87.1% |
| Q1 FY2025 | Mar 31, 2025 | $49.09M | +40.3% |
| Q4 FY2024 | Dec 31, 2024 | $18.22M | -16.9% |
| Q3 FY2024 | Sep 30, 2024 | -$4.77M | -114.4% |
| Q2 FY2024 | Jun 30, 2024 | $19.87M | -26.7% |
| Q1 FY2024 | Mar 31, 2024 | $35.00M | +42.3% |
| Q4 FY2023 | Dec 31, 2023 | $21.92M | +34.4% |
| Q3 FY2023 | Sep 30, 2023 | $33.16M | +261.5% |
| Q2 FY2023 | Jun 30, 2023 | $27.09M | +3083.5% |
| Q1 FY2023 | Mar 31, 2023 | $24.60M | – |
| Q4 FY2022 | Dec 31, 2022 | $16.30M | – |
| Q3 FY2022 | Sep 30, 2022 | $9.17M | +17.8% |
| Q2 FY2022 | Jun 30, 2022 | $851.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.64M | -133.3% |
| Q4 FY2021 | Dec 31, 2021 | -$10.04M | -189.4% |
| Q3 FY2021 | Sep 30, 2021 | $7.78M | -45.0% |
| Q2 FY2021 | Jun 30, 2021 | -$4.23M | – |
| Q1 FY2021 | Mar 31, 2021 | $13.94M | +317.3% |
| Q4 FY2020 | Dec 31, 2020 | $11.23M | +129.5% |
| Q3 FY2020 | Sep 30, 2020 | $14.16M | -15.7% |
| Q2 FY2020 | Jun 30, 2020 | -$109.00K | -100.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.34M | -83.7% |
| Q4 FY2019 | Dec 31, 2019 | $4.89M | -75.7% |
| Q3 FY2019 | Sep 30, 2019 | $16.80M | -10.0% |
| Q2 FY2019 | Jun 30, 2019 | $18.76M | +20.5% |
| Q1 FY2019 | Mar 31, 2019 | $20.51M | +39.2% |
| Q4 FY2018 | Dec 31, 2018 | $20.13M | +39.8% |
| Q3 FY2018 | Sep 30, 2018 | $18.66M | +13.6% |
| Q2 FY2018 | Jun 30, 2018 | $15.58M | +10.5% |
| Q1 FY2018 | Mar 31, 2018 | $14.73M | +30.0% |
| Q4 FY2017 | Dec 31, 2017 | $14.40M | +102.5% |
| Q3 FY2017 | Sep 30, 2017 | $16.43M | – |
| Q2 FY2017 | Jun 30, 2017 | $14.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.11M | – |
See a number that looks wrong?